Search

In total, all 210 patients complied with the inclusion criteria and agreed to participate in the study: 117 (55.7%) patients on biologics, 47 (22.4%) on conventional immunosuppressive therapy and 46 (21.9%) on topical therapy. Treatment safety concerns were significantly more common in the biologics-treated patients, where 40.7% either agreed/strongly agreed of having experienced an increased risk of COVID-19 infection as compared to 21.3% in the conventional systemic group ( I P i < 0.01) and 10.9% in the topical therapy group ( I P i < 0.00001) (Fig. However, the results of our study show that although patients on biologic therapy had more anxiety and treatment safety concerns than patients in the other treatment groups, they did not want to discontinue or interrupt their treatment. [Extracted from the article]